ECM Prosthetic Valve Crosslinking for Calcification Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional prosthetic heart valves face issues such as tissue calcification, the need for anticoagulation agents causing side effects, and the inability to remodel into normal tissue capable of regeneration, often requiring open heart surgery with a heart-lung machine.
Innovation Solution
Development of prosthetic tissue valves using extracellular matrix (ECM) compositions derived from mammalian tissues, incorporating biologically active agents and pharmacological agents to induce host tissue proliferation, bioremodeling, and regeneration, with secure attachment mechanisms to cardiovascular structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prosthetic tissue valves are used, then valve replacement can be achieved, but tissue calcification occurs over time reducing durability
Solution Approach 1:
The patent changes the material parameters of the prosthetic valve by using glutaraldehyde-crosslinked tissue at controlled humidity levels (below 65% relative humidity during storage and implantation). This parameter control prevents calcium deposition while maintaining tissue structural integrity, thereby improving long-term durability without calcification
Solution Approach 2:
The invention creates a composite structure by impregnating the glutaraldehyde-crosslinked tissue matrix with calcium phosphate materials that mimic natural bone mineral. This composite approach allows the valve to integrate with calcified tissue structures while maintaining flexibility and preventing pathological calcification through the controlled crosslinking process
2Reliability
If mechanical prosthetic valves are used, then durable valve function is achieved, but anticoagulation agents are required causing side effects
Solution Approach 1:
The patent replaces mechanical valve components with biologically active tissue materials that are resistant to thrombus formation. The glutaraldehyde-crosslinked tissue structure and controlled humidity environment create a non-thrombogenic surface that eliminates the need for mechanical moving parts and associated anticoagulation requirements, thereby removing harmful side effects while maintaining reliable valve function
Solution Approach 2:
By controlling the crosslinking parameters and humidity levels during fabrication and storage, the patent modifies the surface properties of the prosthetic tissue to be thromboresistant. This parameter optimization allows the valve to function reliably without requiring anticoagulation therapy, eliminating the harmful side effects associated with blood thinning medications
3Reliability
If conventional prosthetic valves are implanted, then valve replacement is achieved, but open heart surgery with heart-lung machine is required
Solution Approach 1:
The patent performs preliminary actions by pre-crosslinking the tissue valve in a controlled environment before implantation. The valve is fabricated and stabilized outside the body with optimized humidity and chemical treatment, allowing for simplified implantation procedures that do not require complex cardiopulmonary bypass systems, thereby reducing surgical complexity while ensuring reliable valve replacement
Solution Approach 2:
The invention uses an intermediary delivery system that allows the pre-prepared crosslinked tissue valve to be implanted through less invasive approaches. The controlled crosslinking creates a stable structure that can be delivered and deployed without requiring the patient to undergo full open heart surgery with heart-lung machine support, thus reducing procedural complexity
4Strength
If prosthetic tissue valves are used, then initial structural integrity is achieved, but inability to remodel into normal tissue prevents regeneration
Solution Approach 1:
The patent creates a dynamic tissue structure where the glutaraldehyde crosslinking density is controlled to allow progressive remodeling. The crosslinked matrix provides initial structural integrity but maintains sufficient porosity and biochemical activity to permit host cell infiltration and gradual transformation into native tissue, thereby achieving both strength and adaptability through time-dependent structural evolution
Solution Approach 2:
The invention optimizes the crosslinking parameters and humidity control to create a matrix with specific pore sizes and biochemical properties that guide tissue regeneration. By carefully adjusting these parameters, the valve provides initial structural support while simultaneously creating an environment conducive to host tissue infiltration and remodeling into functional native tissue over time
Data Source
AI summary
A prosthetic valve comprising a conical shaped sheet member comprising an extracellular matrix (ECM) composition and an internal multi-link support stent structure, the sheet member having a plurality of open slit regions that are disposed uniformly on linear planes that are parallel to the sheet member longitudinal axis, and a proximal annulus engagement end diameter and length ratio in the range of 5:1 to 2:1.